<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028378</url>
  </required_header>
  <id_info>
    <org_study_id>T-CAT-001</org_study_id>
    <nct_id>NCT01028378</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Topography-Guided LASIK to Treat Myopia and Hyperopia</brief_title>
  <official_title>Topography-Guided LASIK Using the ALLEGRETTO WAVE Eye-Q 400 Hz Excimer Laser System For the Treatment of Manifest and Cornea Based Myopic and Hyperopic Optical Errors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Consultants, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>WaveLight AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Research Consultants, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This purpose of this study is to evaluate the safety and effectiveness of a topography-based
      custom ablation treatment using the ALLEGRETTO WAVEÂ® Eye-Q 400 Hz laser system for treating
      myopia and hyperopia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) +/- 0.50 D</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) +/- 1.00 D</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) +/- 2.00 D</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Eyes With Uncorrected Visual Acuity (UCVA) 20/20 or Better</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Eyes With UCVA 20/40 or Better if BSCVA 20/20 or Better Preoperatively</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Eyes With Loss of 2 or More Lines Best Spectacle-Corrected Visual Acuity (BSCVA)</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Eyes With Best Spectacle-Corrected Visual Acuity (BSCVA) Worse Than 20/40</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Eyes With an Increase &gt; 2D Cylinder (Spherical Only)</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Eyes With Best Spectacle-corrected Visual Acuity (BSCVA) Worse Than 20/40 if 20/20 or Better Preoperatively</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Myopia</condition>
  <condition>Hyperopia</condition>
  <arm_group>
    <arm_group_label>Topography-guided LASIK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topography-guided LASIK for Myopia or Hyperopia</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</intervention_name>
    <arm_group_label>Topography-guided LASIK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older;

          -  Signed Informed Consent;

          -  Willingness and ability to comply with schedule for follow-up visits;

          -  be a candidate for topography guided LASIK treatment of myopia or hyperopia in both
             eyes based on your doctors examination of your eyes;

          -  Intended treatment is targeted for emmetropia;

          -  Stable refraction (0.5 D or less change in manifest refraction spherical equivalent
             (MRSE) per year) for 12 months or longer, based on previous clinical records or
             prescription history (e.g., old glasses/contact lens prescriptions).

          -  Able to obtain a reliable corneal topography that can be used to determine the T-CAT
             treatment plan;

          -  Best spectacle-corrected visual acuity (BSCVA) 20/25 or better in each eye;

          -  Less than 0.75 D spherical equivalent (SE) difference between cycloplegic and manifest
             refractions.

          -  Is not a contact lens wearer or, if wearing contact lenses, has discontinued wearing
             contact lenses for the required period of time and completed the contact lens
             stability check;

          -  be able to maintain your eye position steady during the course of the treatment.

        Exclusion Criteria:

          -  History of prior refractive treatment;

          -  Mixed astigmatism refractive error;

          -  Lenticular astigmatism that, in the investigator's opinion, is clinically significant;

          -  Corneal topography showing evidence of keratoconus, keratoconus suspect, forme fruste
             keratoconus, pellucid marginal degeneration, or other topographic abnormality that
             would place the eye at risk for developing post-refractive corneal ectasia;

          -  Treatment plan for T-CAT would predict a residual stromal bed thickness less than 250
             microns;

          -  History or current evidence of corneal or other anterior segment disease that might
             reasonably be expected to affect the outcome of treatment (e.g., herpes simplex
             keratitis, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal
             dystrophy, etc.);

          -  Evidence of retinal vascular disease;

          -  Female patients who are pregnant or lactating or plan to become pregnant during the
             course of the study;

          -  A known sensitivity to study medications;

          -  Nystagmus or any other condition that would prevent a steady gaze during the LASIK
             treatment or other diagnostic tests;

          -  Corneal dystrophy or corneal guttae;

          -  Pathology involving the iris (e.g., coloboma, tears, cuts, significant pigment loss,
             etc.);

          -  Residual, recurrent or active ocular pathology;

          -  Previous intraocular or corneal surgery that might confound the outcome or increase
             the risk of the study;

          -  Acute or chronic illness that might increase the risk or confound the outcome of the
             study (e.g., diagnosed autoimmune disease, systemic connective tissue disease,
             clinically significant atopic disease, diabetes mellitus, etc.)

          -  The use of systemic medications that may confound the outcome or increase the risk of
             the study, including, but not limited to: corticosteroids and antimetabolites;

          -  Intraocular pressure &gt; 23 mm Hg, a history of glaucoma, or a glaucoma suspect;

          -  An increased risk for developing strabismus after treatment (applicable only to
             treatment of hyperopic refractive errors);

          -  Presence or history of any other condition or finding that, in the investigator's
             opinion, makes the patient unsuitable as a candidate for LASIK or study participation
             or may confound the outcome of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doyle Stulting, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Woolfson Eye Institute/Medical Monitor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Milauskas Eye Institute</name>
      <address>
        <city>La Quinta</city>
        <state>California</state>
        <zip>92253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gordon &amp; Weiss Vision Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woolfson Eye Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Vision</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bond Eye Associates</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durrie Vision</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TLC Laser Eye Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Eye Institute</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser Vision of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Eye Care Laser Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <results_first_submitted>January 28, 2014</results_first_submitted>
  <results_first_submitted_qc>March 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 11, 2016</results_first_posted>
  <last_update_submitted>March 18, 2016</last_update_submitted>
  <last_update_submitted_qc>March 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Topography-guided LASIK</title>
          <description>Topography-guided LASIK for Myopia or Hyperopia
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="212">212 participants (249 eyes) with myopia</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="195">195 participants (230 eyes) with myopia</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adminstrative Reasons</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>212 participants (249 eyes)</population>
      <group_list>
        <group group_id="B1">
          <title>Topography-guided LASIK</title>
          <description>Topography-guided LASIK for Myopia or Hyperopia
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="212"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) +/- 0.50 D</title>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topography-guided LASIK</title>
            <description>Topography-guided LASIK for Myopia or Hyperopia
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) +/- 0.50 D</title>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.78" lower_limit="91.8" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) +/- 1.00 D</title>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topography-guided LASIK</title>
            <description>Topography-guided LASIK for Myopia or Hyperopia
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) +/- 1.00 D</title>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.57" lower_limit="98.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) +/- 2.00 D</title>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topography-guided LASIK</title>
            <description>Topography-guided LASIK for Myopia or Hyperopia
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) +/- 2.00 D</title>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes With Uncorrected Visual Acuity (UCVA) 20/20 or Better</title>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topography-guided LASIK</title>
            <description>Topography-guided LASIK for Myopia or Hyperopia
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Uncorrected Visual Acuity (UCVA) 20/20 or Better</title>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.61" lower_limit="89.2" upper_limit="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes With UCVA 20/40 or Better if BSCVA 20/20 or Better Preoperatively</title>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topography-guided LASIK</title>
            <description>Topography-guided LASIK for Myopia or Hyperopia
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With UCVA 20/40 or Better if BSCVA 20/20 or Better Preoperatively</title>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.56" lower_limit="98.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes With Loss of 2 or More Lines Best Spectacle-Corrected Visual Acuity (BSCVA)</title>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topography-guided LASIK</title>
            <description>Topography-guided LASIK for Myopia or Hyperopia
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Loss of 2 or More Lines Best Spectacle-Corrected Visual Acuity (BSCVA)</title>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" lower_limit="0" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes With Best Spectacle-Corrected Visual Acuity (BSCVA) Worse Than 20/40</title>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topography-guided LASIK</title>
            <description>Topography-guided LASIK for Myopia or Hyperopia
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Best Spectacle-Corrected Visual Acuity (BSCVA) Worse Than 20/40</title>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes With an Increase &gt; 2D Cylinder (Spherical Only)</title>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topography-guided LASIK</title>
            <description>Topography-guided LASIK for Myopia or Hyperopia
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With an Increase &gt; 2D Cylinder (Spherical Only)</title>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes With Best Spectacle-corrected Visual Acuity (BSCVA) Worse Than 20/40 if 20/20 or Better Preoperatively</title>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topography-guided LASIK</title>
            <description>Topography-guided LASIK for Myopia or Hyperopia
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Best Spectacle-corrected Visual Acuity (BSCVA) Worse Than 20/40 if 20/20 or Better Preoperatively</title>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Topography-guided LASIK</title>
          <description>Topography-guided LASIK for Myopia or Hyperopia
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BSCVA loss of 2 or more lines</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Retinal Detachments</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara S. Fant, Pharm.D.</name_or_title>
      <organization>Clinical Research Consultants, Inc.</organization>
      <phone>513-961-8200</phone>
      <email>bsfant@crc-regulatory.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

